GVHD and miR: good things in small packages.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2020
   Review
2. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.Leukemia · 2019
   Article
3. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.Blood · 2018
   Article
4. Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes.Frontiers in immunology · 2017
   Review
5. B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2016
   Review

Corrections and comments

• Comment on
  MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.2015

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as